Prognostic significance of flow cytometric minimal residual disease assessment after the first induction course in Chinese childhood acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 134-138

  Xu, Xiao Jun ^a   Feng, Jian Hua ^a   Tang, Yong Min ^a,b   Shen, Hong Qiang ^a,b   Song, Hua ^a   Yang, Shi Long ^a   Shi, Shu Wen ^a   Xu, Wei Qun ^a  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Childhood; Minimal residual disease; Multiparameter fl ligature ow cytometry; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM, RESIDUAL; PROGNOSIS; RECURRENCE; REMISSION INDUCTION;

EID: 84872373905     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.002     Document Type: Article

References (18)

1. Meshinchi S., Arceci R.J. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007, 12:341-355.
2. Rubnitz J.E. Childhood acute myeloid leukemia. Curr Treat Options Oncol 2008, 9:95-105.
3. Kaspers G.J., Zwaan C.M. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007, 92:1519-1532.
4. Pession A., Rondelli R., Basso G., Rizzari C., Testi A.M., Fagioli F., et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005, 19:2043-2053.
5. Borowitz M.J., Devidas M., Hunger S.P., Bowman W.P., Carroll A.J., Carroll W.L., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study. Blood 2008, 111:5477-5485.
6. Xu X.J., Tang Y.M., Shen H.Q., Song H., Yang S.L., Shi S.W., et al. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia. Leuk Res 2012, 36:1022-1027.
7. Sievers E.L., Lange B.J., Alonzo T.A., Gerbing R.B., Bernstein I.D., Smith F.O., et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003, 101:3398-3406.
8. Coustan-Smith E., Ribeiro R.C., Rubnitz J.E., Razzouk B.I., Pui C.H., Pounds S., et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003, 123:243-252.
9. van der Velden V.H., van der Sluijs-Geling A., Gibson B.E., te Marvelde J.G., Hoogeveen P.G., Hop W.C., et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010, 24:1599-1606.
10. Gaipa G., Cazzaniga G., Valsecchi M.G., Panzer-Grumayer R., Buldini B., Silvestri D., et al. Time point-dependent concordance of flow cytometry and RQ-PCR inminimal residual disease detection in childhood acute lymphoblasticleukemia. Haematologica 2012, 97:1582-1593.
11. Neale G.A., Coustan-Smith E., Stow P., Pan Q., Chen X., Pui C.H., et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004, 18:934-938.
12. Kern W., Schoch C., Haferlach T., Voskova D., Hiddemann W., Schnittger S. Complemental roles for multiparameter flow cytomety and quantitative RT-PCR for the quantification of minimal residual disease in patients with acute myeloid leukemia. Blood 2003, 102:65a-70a.
13. Sievers E.L., Lange B.J., Buckley J.D., Smith F.O., Wells D.A., Daigneault-Creech C.A., et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996, 88:1483-1488.
14. Langebrake C., Creutzig U., Dworzak M., Hrusak O., Mejstrikova E., Griesinger F., et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. J Clin Oncol 2006, 24:3686-3692.
15. Xu X.J., Tang Y.M., Song H., Yang S.L., Shi S.W., Wei J. Long-term outcome of childhood acute myeloid leukemia in a developing country: experience from a children's hospital in China. Leuk Lymphoma 2010, 51:2262-2269.
16. Mrozek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18:115-136.
17. San Miguel J.F., Vidriales M.B., Lopez-Berges C., Diaz-Mediavilla J., Gutierrez N., Canizo C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98:1746-1751.
18. Feller N., van der Pol M.A., van Stijn A., Weijers G.W., Westra A.H., Evertse B.W., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004, 18:1380-1390.